Quarterly ResultApr 30, 2026, 07:07 AM
BMY Q1 Revenue +3% to $11.5B; GAAP EPS $1.31; Reaffirms 2026 Guidance
AI Summary
Bristol Myers Squibb reported first-quarter 2026 revenues of $11.5 billion, a 3% increase (+1% Ex-FX), with GAAP EPS of $1.31, up 9%. The Growth Portfolio saw a 12% increase to $6.2 billion, driven by strong performance from Camzyos, Breyanzi, and Reblozyl. The company reaffirmed its 2026 financial guidance, with revenues and non-GAAP EPS trending towards the upper end of the ranges. Key pipeline updates include FDA approvals for Opdivo and Sotyktu, and positive clinical trial data for Camzyos, mezigdomide, iza-bren, and Reblozyl.
Key Highlights
- Total revenues increased 3% (+1% Ex-FX) to $11.5 billion.
- GAAP EPS was $1.31 (+9%); non-GAAP EPS was $1.58 (-12%).
- Growth Portfolio revenues grew 12% (+9% Ex-FX) to $6.2 billion.
- Reaffirmed 2026 revenue guidance of ~$46.0-$47.5 billion.
- Reaffirmed 2026 non-GAAP EPS guidance of $6.05-$6.35.
- Eliquis revenues rose 16% (+13% Ex-FX) to $4.137 billion.
- Sotyktu received FDA approval for active psoriatic arthritis.
- Opdivo received FDA and EC approvals for classical Hodgkin Lymphoma.